(HealthDay News) — A personalized vaccine held an aggressive group of cancers in check among more than half of patients who received it in a small, preliminary trial, researchers report. HER2-positive cancers …
Read more via WebMD Health https://ift.tt/2y3xTXV
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.